Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 346Neoplasms 247Prostatic Neoplasms 198Colorectal Neoplasms 151Lung Neoplasms 130Carcinoma, Non-Small-Cell Lung 108Leukemia, Myeloid, Acute 107Pancreatic Neoplasms 98Multiple Myeloma 89Glioblastoma 77Precursor Cell Lymphoblastic Leukemia-Lymphoma 73Brain Neoplasms 73Head and Neck Neoplasms 72Carcinoma, Hepatocellular 67Squamous Cell Carcinoma of Head and Neck 65Melanoma 62Uterine Cervical Neoplasms 61Ovarian Neoplasms 59Neoplasm Metastasis 55Rectal Neoplasms 52Hematologic Neoplasms 50Recurrence 48Stomach Neoplasms 47Glioma 46Myelodysplastic Syndromes 45Motor Activity 45Triple Negative Breast Neoplasms 44Carcinoma, Renal Cell 44Endometrial Neoplasms 43Sarcoma 41

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Allogeneic Stem Cell Transplantation × 30 days × Clear all
NCT06297629 2026-05-15

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Withdrawn

Allogeneic Stem Cell Transplantation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡